Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2026
Viva Biotech Upgrades MARS Multimodal Algorithm Platform
During the reporting period, Viva Biotech's CADD/AIDD team upgraded and launched the MARS multimodal comprehensive algorithm platform, with the core Pep2MARS algorithm platform establishing technical barriers in peptides, cyclic peptides and complex macrocyclic compounds. The platform upgraded three underlying modules, V-Scepter, V-Orb and V-Mantle.
2026
Viva Biotech Reports 2026 Interim Results
Viva Biotech Holdings (1873.HK) reported interim results for the six months ended June 30, 2026, with total revenue of RMB 1,006.5 million, up 21.0% year on year, gross profit of RMB 341.7 million, up 0.7%, and gross margin of 34.0%. Net profit was RMB 100.9 million and adjusted non-IFRS net profit was RMB 128.3 million, both down from the prior-year period, mainly due to lower investment income, unfavorable foreign exchange movements and higher R&D expenses from new business initiatives. CRO revenue was RMB 405.1 million and Langhua Pharmaceutical CDMO revenue was RMB 601.4 million, up about 47.0% year on year.
2021
Viva Biotech reports 2021 interim results
Viva Biotech announced its interim results for the six months ended June 30, 2021, reporting revenue of approximately RMB1,026.5 million, gross profit of approximately RMB316.3 million, and adjusted net profit of approximately RMB204.9 million.